These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36481378)

  • 1. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
    Jfri A; Smith JS; Larocca C
    J Am Acad Dermatol; 2023 May; 88(5):1164-1166. PubMed ID: 36481378
    [No Abstract]   [Full Text] [Related]  

  • 2. Unmasking a masquerader: Mycosis fungoides unveiled after dupilumab treatment.
    Joshi TP; Duvic M
    J Am Acad Dermatol; 2023 Jun; 88(6):e305-e306. PubMed ID: 36858155
    [No Abstract]   [Full Text] [Related]  

  • 3. Progression of CD8-positive Sézary syndrome from mycosis fungoides following dupilumab treatment.
    Fujii K; Yoshizaki A; Matsuoka A; Baba N; Ohshima K; Kanekura T
    Eur J Dermatol; 2024 Jun; 34(3):294-296. PubMed ID: 39015963
    [No Abstract]   [Full Text] [Related]  

  • 4. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
    Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
    Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma.
    Deschamps O; Ram-Wolff C; Beylot-Barry M; Grange F; Skowron F; Dereure O; Boulinguez S; Aubin F; Ingen-Housz-Oro S; Bagot M;
    Br J Dermatol; 2019 Feb; 180(2):423-424. PubMed ID: 30298903
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
    Querfeld C; Zain J; Rosen ST
    Cancer Treat Res; 2019; 176():225-248. PubMed ID: 30596221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome.
    Alenezi F; Girard C; Bessis D; Guillot B; Du-Thanh A; Dereure O
    Acta Derm Venereol; 2021 Feb; 101(2):adv00384. PubMed ID: 33313939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab, Atopic Dermatitis, and Mycosis Fungoides-New Insights on an Evolving Story.
    Guitart J
    JAMA Dermatol; 2023 Nov; 159(11):1177-1178. PubMed ID: 37851433
    [No Abstract]   [Full Text] [Related]  

  • 9. Dupilumab Treatment in Two Patients with Cutaneous T-cell Lymphomas.
    Lazaridou I; Ram-Wolff C; Bouaziz JD; Bégon E; Battistella M; Rivet J; Jachiet M; Bagot M; de Masson A
    Acta Derm Venereol; 2020 Sep; 100(16):adv00271. PubMed ID: 32556342
    [No Abstract]   [Full Text] [Related]  

  • 10. Changes to Registered and Pivotal Clinical Trials after the 2011 Tri-Societies Guidelines for Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sézary Syndrome.
    Gunter SJ; Kim EJ
    J Invest Dermatol; 2024 Apr; 144(4):855-861.e1. PubMed ID: 37925066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome.
    Molloy K; Vico C; Ortiz-Romero PL; Scarisbrick JJ
    Br J Dermatol; 2021 May; 184(5):978-981. PubMed ID: 33314065
    [No Abstract]   [Full Text] [Related]  

  • 13. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
    Quadri I; Reneau JC; Hanel W; Chung CG
    Front Immunol; 2023; 14():1291259. PubMed ID: 38022633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
    Lewis DJ; Rook AH
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State of the art therapy of mycosis fungoides and Sézary syndrome.
    Kemme DJ; Bunn PA
    Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosing mycosis fungoides after initiation of therapy with dupilumab: a case report and literature review.
    Yan D; Ramachandran V; Weston G; Kim RH; Latkowski JA
    Int J Dermatol; 2023 Sep; 62(9):e500-e503. PubMed ID: 36946434
    [No Abstract]   [Full Text] [Related]  

  • 18. CD30
    Ellis A; Christensen LF; Sharma T; Meyerson H; Kord H; Cooper KD
    J Am Acad Dermatol; 2021 Feb; 84(2):530-532. PubMed ID: 32437721
    [No Abstract]   [Full Text] [Related]  

  • 19. Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres.
    Buffon S; Alberti Violetti S; Avallone G; Venegoni L; Marzano AV; Mastorino L; Fava P; Ribero S; Quaglino P; Ortoncelli M; Ferrucci SM
    Clin Exp Dermatol; 2023 Nov; 48(12):1376-1378. PubMed ID: 37596961
    [No Abstract]   [Full Text] [Related]  

  • 20. Comment on "Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab".
    Cohen JM; Damsky W; Girardi M
    J Am Acad Dermatol; 2022 Dec; 87(6):e241-e242. PubMed ID: 35933070
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.